Second-line treatment of small-cell lung cancer with the camptothecin- derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG)

Annals of Oncology

Volumn 11, Issue 2, 2000, Pages 207-210

  Sessa, C ^b   Wanders, J ^a   Roelvink, M ^a   Dombernowsky, P ^c   Nielsen, D ^c   Morant, R ^c   Drings, P ^c   Wissel, P ^c   Hanauske, A R ^c  

^a EORTC New Drug Development Office   (Netherlands)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

^c NONE

Author keywords

Camptothecin analogue; Phase II; Second line treatment; Small cell lung cancer

Indexed keywords

CAMPTOTHECIN DERIVATIVE; LURTOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034066518     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008372404504     Document Type: Article

References (11)

1. Wall ME, Wani MC, Nicholas AW et al. Synthesis and structure activity of novel camptothecin analogs. J Med Chem 1993; 36: 2691-700.
2. Emerson DL, Besterman JM, Brown HR et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 1995; 55: 603-9.
3. Glaxo Wellcome Research and Development Clinical Investigator's Brochure. Research Triangle Park, North Carolina: Glaxo Wellcome Research and Development 1993.
4. Eckhardt SG. Baker SD, Eckardt JR et al. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin Cancer Res 1998; 4: 595-604.
5. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15: 2090-6.
6. Giaccone G, Donadio G, Bonardi G et al. Teniposide in the treatment of small-cell lung cancer: The influence of prior chemotherapy. J Clin Oncol 1988; 6: 1264-70.
7. Schellens JHM, Heinrich B, Lehnert M et al. Population pharmacokinetic and dynamic analysis of the topoisomerase inhibitor Lurtotecan in phase II studies. Eur J Cancer (submitted)
8. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1990; 47: 207-14.
9. Gehan E. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961; 13: 346-53.
10. Colbern GT, Dykes DJ, Engbers C et al. Encapsulation of the topoisomerase I inhibitor GI147211C in pegylated (Stealth) liposomes: Pharmacokinetics and antitumor activity in HT29 Colon tumor xenografts. Clin Cancer Res 1998; 4: 3077-82.
11. Hamilton M, Meyer DJ, Desjardins JP et al. Pharmacokinetics, distribution and toxicology of NX211 (liposomal/lurtotecan) in mice and rats. Proc Am Soc Clin Oncol 1999; 18: 177a (Abstr 680).